dapiglutide
Peptideexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 14, 2019 (NCT03994549)
Timeline
Indications
Mechanism of action
GLP1R agonist
GLP2R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314980 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06758583 | Phase 1 | Dec 23, 2024 | Profil GmbH, Zealand Pharma |
| NCT06000891 | Phase 1 | Sep 15, 2023 | Profil GmbH, Zealand Pharma |
| NCT05788601 | Phase 2 | Apr 27, 2023 | University of Copenhagen, Zealand Pharma |
| NCT04612517 | Early Phase 1 (Phase 1) | Oct 26, 2020 | Profil GmbH, Zealand Pharma |
| NCT03994549 | Early Phase 1 (Phase 1) | Jun 14, 2019 | Profil GmbH, Zealand Pharma |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zealand Pharma | For profit | 5 | 4 | 2 | 2019 |
| Profil GmbH | For profit | 4 | 0 | 1 | 2019 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1